NEU

1.15%

$12.34

NEUREN PHARMACEUTICALS LIMITED

Market Cap $1.577B Add to my watchlist

Healthcare Biotechnology

Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing... Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing therapies for neurodevelopmental disorders. The Company is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The Company has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of NNZ-259 for Rett syndrome and Fragile X syndrome.More

Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated mission to be at the heart of cancer care. WEBINAR: What investors should know about what it takes for ASX-listed companies to get medical developments...

Latest Threads

Tag

Subject

NEU

Share Price

227 228 229

11:31

13K

6.4M

11:31

Last post offfarmY

13K

6.4M

NEU

Acadia

18 19 20

27/12/24

1.1K

552K

27/12/24

Last post Outlander2

1.1K

552K

NEU

Pipeline-in-a-drug

2 3 4

27/12/24

224

101K

27/12/24

Last post turbo

224

101K

NEU

Ann: Update - Notification of buy-back - NEU

2 3

24/12/24

131

49K

24/12/24

Last post Garys777

131

49K

NEU

Katelin’s Turn is HERE!!!

3 4 5

23/12/24

278

165K

23/12/24

Last post What A Gas

278

165K

NEU

NEU chart

35 36 37

23/12/24

2.1K

1.1M

23/12/24

Last post Bouncing

2.1K

1.1M

NEU

NEU is materially undervalued

23/12/24

51K

23/12/24

Last post baldwidx

51K

NEU

Angelman trial

20/12/24

42K

20/12/24

Last post Piton72

42K

See All Discussions

Timeline

Update - Notification of buy-back - NEU
18 Dec 08:51	Share

Update - Notification of buy-back - NEU
17 Dec 08:53	Share

Update - Notification of buy-back - NEU
16 Dec 09:13	Share

Update - Notification of buy-back - NEU
13 Dec 08:55	Share

Priority Review Voucher sale complete
12 Dec 09:31	Share

Update - Notification of buy-back - NEU
12 Dec 09:04	Share

Update - Notification of buy-back - NEU
11 Dec 09:35	Share

Update - Notification of buy-back - NEU
10 Dec 09:12	Share

Update - Notification of buy-back - NEU
09 Dec 08:36	Share

Update - Notification of buy-back - NEU
06 Dec 08:46	Share

Update - Notification of buy-back - NEU
05 Dec 08:19	Share

Update - Notification of buy-back - NEU
04 Dec 08:29	Share

Update - Notification of buy-back - NEU
03 Dec 09:14	Share

Investor presentation, 15 November 2024
15 Nov 10:19	Share

Notification of buy-back - NEU
14 Nov 09:17	Share

Neuren announces A$50m on-market share buy-back program
14 Nov 09:14	Share

Q3 2024 update
07 Nov 10:19	Share

Pause in Trading
07 Nov 10:02	Share

PRV sold for US$150m - Neuren to receive one third
06 Nov 09:26	Share

Updated Share Trading Policy
01 Nov 16:49	Share

Notification of cessation of securities - NEU
28 Oct 16:30	Share

DAYBUE receives marketing authorization in Canada
17 Oct 09:30	Share

NEU continues PMS P3 preparations after positive FDA meeting
07 Oct 09:32	Share

H1 2024 financial results
27 Aug 09:17	Share

Half Yearly Report and Accounts
27 Aug 09:12	Share

Investor roadshow presentation, 19 August 2024
19 Aug 09:33	Share

Change of Director's Interest Notice - J Basile
16 Aug 16:49	Share

NNZ-2591 Angelman top-line results presentation
09 Aug 10:43	Share

Phase 2 trial shows significant improvements in Angelman
09 Aug 10:01	Share

Trading Halt
07 Aug 10:08	Share

View More

(20min delay)
Last $12.34		Change 0.140(1.15%)		Mkt cap ! $1.577B

Open	High	Low	Value	Volume
$12.20	$12.40	$12.15	$3.684M	299.3K

Buyers (Bids)

No.	Vol.	Price($)
3	1507	$12.34

Sellers (Offers)

Price($)	Vol.	No.
$12.36	4256	1

View Market Depth

No.	Vol.	Price($)
1	15	12.240
1	200	12.200
1	1000	12.190
1	1200	12.170
4	4024	12.150

Price($)	Vol.	No.
12.360	4256	1
12.370	1355	1
12.400	2000	1
12.460	2000	1
12.570	524	2

Last trade - 16.10pm 27/12/2024 (20 minute delay)

NEU (ASX) Chart

NEUREN PHARMACEUTICALS LIMITED

Latest Threads

Timeline

Featured News

Latest Videos

Neuren Pharmaceuticals (ASX:NEU) partner drug approved as first treatment for Rett syndrome

13 Mar 2023 10:53 (AEDT)

Neuren Pharmaceuticals (ASX:NEU) receives FDA approval for Prader-Willi syndrome phase II trial

23 Jan 2023 11:16 (AEDT)

Latest Articles

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Neuren has confirmed it's received "positive" FDA responses for its Phase III trial to treat children with Phelan-McDermid syndrome.

Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress

Neuren (ASX:NEU) was the biggest faller in lunchtime trades on Friday after announcing some children were "minimally improved" in phase 2 of a trial treating children with Angelman syndrome.

Neuren flags Q4 DAYBUE sales of US$87m but shares take nosedive right out the gate

Neuren (ASX:NEU) shares were down -12% out the gate on Wednesday per CBOE live pricing, even as the stock flagged US$87.1M in sales of its flagship drug DAYBUE in Q4 of 2023.

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News